CHMP5 and hematologic disorder: In conclusion, these data showed a significant difference in the magnitude of anti-Spike Ab titers between the two cohorts, with patients who underwent cell therapies for hematological malignancies showing lower Ab titers and a proportional lower ability of cross-recognition of different Spike-RBD proteins but maintaining the ability to neutralize wildtype WA1 and the Delta variant.